A strategy update with IDL Diagnostics was held on November 27th at Redeye, where CEO Anders Hultman and the management team presented recent achievements, spotlighted key initiatives, and discussed future opportunities looking toward 2026 and beyond. After their...
Redeye interview with Anders Hultman CEO, commenting on the Interim Report Q3 2025 IDL Diagnostics (Q3 Interview): Redeye talks with CEO Anders Hultman IDL Diagnostics: CEO Anders Hultman and CFO Ellen Dittberner present the company’s Q3’25 results – November...
Beckman Coulter has been one of IDL Biotech's most successful tumor markers distributors, and has sold the products in the Czech Republic and Slovakia for many years. With Beckman Coulter now taking over the global distribution rights for the company's tumor markers,...
The registration of TUBEX TF has been approved in Indonesia. Read the press release here
IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with PHM Diagnostic Lab Ltd in Zimbabwe. Read the press release here
Kina har i många år varit ledande i användningen av tumörmarkörer. IDL Biotech har nu tecknat avtal med det kinesiska företaget ZECEN Biotech som avser en automatisering av analysprocessen för tumörmarkören TPS® på ZECEN Biotechs instrument. TPS® är en tumörmarkör som...
IDL has signed a new distribution agreement in Uganda Read the press release here
Achieving accurate laboratory diagnosis of typhoid fever: a review and meta-analysis of TUBEX® TF clinical performance. Read the article here: Read the press release here:
IDL has signed a distribution agreement in Malaysia Read the press release here
IDL has signed two new distributions agreements. Please read the press release here (Asia) and here (Kenya)
